HIGHLIGHTS
- who: Fenneke Zwierenga from the Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands have published the article: High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial, in the Journal: (JOURNAL)
- what: The primary reason for discon tinuation was progressive disease in 14 patients (56%). The study showed an objective response rate (ORR) of 24% and a disease control rate (DCR) of 85% , in which the responders all harbored an EGFRex20 + mutation in the loop following C . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.